Building Pharma Brands That Win

In pharma, the brands that win don’t wait for the market to define them. They define themselves through clear, early, and evolving positioning. In this Outcomes Rocket episode, Lumanity’s Natalie Thovmasian and Liv Yates share why positioning is a strategic driver across the entire pharma lifecycle, how to shape it before clinical data, and how to keep it sharp as markets shift. If you’re building or scaling a pharma brand, this is a must-listen conversation.

Launching a pharma product is a high-stakes, pressure-filled marathon where poor planning shows up too late to fix. In this episode, Andrew Mooney and Laurence Cooper break down how early planning, focused strategy, and disciplined execution help smaller pharma teams succeed in high-pressure launches. If you’re preparing for a first-time or early-stage pharma launch, this conversation breaks down exactly how to stay focused, avoid costly surprises, and execute with confidence.

Most pharma launch frameworks don’t fail because they lack structure; they fail because they become rigid checklists that suppress strategic thinking. In this episode, Kirsty Tait and Jeff Hart explain that scaling launches requires moving beyond inflexible models toward standardized, yet adaptable systems supported by strong governance, centralized visibility, and execution-focused culture. If your launch process feels slow, inconsistent, or overly complex, this conversation offers a practical blueprint for scaling without losing speed or impact. 

In the volatility caused by policy convergence, the future belongs to organizations that can intelligently navigate inflection points that precede launch. In this episode, Steve Mather explains how IRA time horizons, Europe’s JCA, and MFN cross-border pricing dynamics are creating downstream constraints that make “best science” and “commercial excellence” alone insufficient. He highlights the new reality that value is won or lost at a small number of irreversible decision points, meaning companies must move commercial thinking further upstream with early, integrated planning essential for success. 

Portfolio positioning is essential when pharma companies have multiple assets in the same disease area. In this episode, Jakub Kaczor and Peter Smith of Lumanity discuss how focused R&D can unintentionally create internal competition and why co-positioning must begin early in development. They share how following a structured process, grounded in market reality, clear governance, and proper incentives help teams align on a stronger portfolio strategy. Ultimately, they emphasize the importance of portfolio co-positioning to inform clear go to market approach and customer engagement.